{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:09:03Z","timestamp":1774375743248,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jacl.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T02:19:28Z","timestamp":1520561968000},"page":"604-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency"],"prefix":"10.1016","volume":"12","author":[{"given":"Don P.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Marulkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Hamby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacl.2018.02.020_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","article-title":"Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease","volume":"58","author":"Bernstein","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency\u2013an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.02.020_bib3","series-title":"Metabolic and Molecular Bases of Inherited Disease","article-title":"Lysosomal acid lipase deficiencies: the Wolman disease\/cholesteryl ester storage disease spectrum","author":"Grabowski","year":"2012"},{"issue":"14","key":"10.1016\/j.jacl.2018.02.020_bib4","first-page":"2628","article-title":"A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease","volume":"19","author":"Cameron","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jacl.2018.02.020_bib5","series-title":"GeneReviews\u00ae","article-title":"Lysosomal acid lipase deficiency","author":"Hoffman","year":"2015"},{"issue":"5","key":"10.1016\/j.jacl.2018.02.020_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacl.2015.07.008","article-title":"Identification and metabolic profiling of patients with lysosomal acid lipase deficiency","volume":"9","author":"Pullinger","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib7","first-page":"99","article-title":"Lysosomal acid lipase deficiency: Wolman disease and cholesteryl ester storage disease","volume":"35","author":"Tylki-Szymanska","year":"2014","journal-title":"Prilozi"},{"issue":"11","key":"10.1016\/j.jacl.2018.02.020_bib8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jclinpath-2012-201302","article-title":"Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis","volume":"66","author":"Reynolds","year":"2013","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.jacl.2018.02.020_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MPG.0b013e31828b36ac","article-title":"Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency","volume":"56","author":"Zhang","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3476(05)81866-9","article-title":"Lovastatin therapy for cholesterol ester storage disease in two sisters","volume":"118","author":"Tarantino","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacl.2018.02.020_bib11","series-title":"Kanuma [package insert]","year":"2015"},{"key":"10.1016\/j.jacl.2018.02.020_bib12","series-title":"Kanuma [summary of product characteristics]","year":"2015"},{"issue":"3","key":"10.1016\/j.jacl.2018.02.020_bib13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.26289","article-title":"Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease","volume":"58","author":"Balwani","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jacl.2018.02.020_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00041433-200410000-00007","article-title":"Lysosomal acid lipase and atherosclerosis","volume":"15","author":"Du","year":"2004","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2018.02.020_bib15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacl.2018.02.020_bib16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0022-2275(20)41629-3","article-title":"Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor","volume":"32","author":"Nigon","year":"1991","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jacl.2018.02.020_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0022-2275(20)38518-7","article-title":"Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation","volume":"29","author":"Chapman","year":"1988","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.jacl.2018.02.020_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000067","article-title":"The composition and metabolism of large and small LDL","volume":"25","author":"Diffenderfer","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2018.02.020_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2012.09.010","article-title":"Small dense LDL: an emerging risk factor for cardiovascular disease","volume":"414","author":"Hirayama","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.jacl.2018.02.020_bib20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2018.02.020_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2018.02.020_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jacl.2018.02.020_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3909\/ricm0619","article-title":"Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events","volume":"12","author":"McCullough","year":"2011","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacl.2014.09.013","article-title":"Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin","volume":"9","author":"Krauss","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2018.02.020_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11886-016-0724-y","article-title":"CETP inhibition in CVD prevention: an actual appraisal","volume":"18","author":"Di Bartolo","year":"2016","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.jacl.2018.02.020_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"issue":"21","key":"10.1016\/j.jacl.2018.02.020_bib27","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2018.02.020_bib28","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacl.2018.02.020_bib29","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacl.2018.02.020_bib30","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jacl.2017.10.023","article-title":"Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: a population-based study","volume":"12","author":"Christen","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.02.020_bib32","first-page":"S213","article-title":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report","volume":"128 Suppl 5","year":"2011","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jacl.2018.02.020_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40256-017-0216-5","article-title":"Managing cardiovascular risk in lysosomal acid lipase deficiency","volume":"17","author":"Maciejko","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.jacl.2018.02.020_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/clinchem\/41.1.111","article-title":"Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease","volume":"41","author":"Cummings","year":"1995","journal-title":"Clin Chem"},{"issue":"11","key":"10.1016\/j.jacl.2018.02.020_bib35","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0021-9258(17)33434-8","article-title":"Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts","volume":"251","author":"Brown","year":"1976","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jacl.2018.02.020_bib36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1091\/mbc.1.9.661","article-title":"Intercellular transport of lysosomal acid lipase mediates lipoprotein cholesteryl ester metabolism in a human vascular endothelial cell-fibroblast coculture system","volume":"1","author":"Sando","year":"1990","journal-title":"Cell Regul"},{"issue":"35","key":"10.1016\/j.jacl.2018.02.020_bib37","doi-asserted-by":"crossref","first-page":"30624","DOI":"10.1074\/jbc.M111.274381","article-title":"Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease","volume":"286","author":"Bowden","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jacl.2018.02.020_bib38","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1172\/JCI113259","article-title":"Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implications for regulation of apolipoprotein B synthesis","volume":"80","author":"Ginsberg","year":"1987","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jacl.2018.02.020_bib39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.1840110509","article-title":"Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin","volume":"11","author":"Di Bisceglie","year":"1990","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jacl.2018.02.020_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.06.022","article-title":"Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency","volume":"61","author":"Valayannopoulos","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacl.2018.02.020_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1476-511X-10-38","article-title":"Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents","volume":"10","author":"Konrad","year":"2011","journal-title":"Lipids Health Dis"},{"issue":"Suppl C","key":"10.1016\/j.jacl.2018.02.020_bib42","doi-asserted-by":"crossref","first-page":"C58","DOI":"10.1016\/j.ehjsup.2004.04.002","article-title":"Are the effects of statins on HDL-cholesterol clinically relevant?","volume":"6","author":"Chapman","year":"2004","journal-title":"Eur Heart J Suppl"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418301478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418301478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T18:22:06Z","timestamp":1660587726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418301478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1933287418301478"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.02.020","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}